Veppanu (vepdegestrant) FDA Approval — First PROTAC Cancer Drug. ESR1-Mutated Breast Cancer PFS 5.0 Months
A new modality of cancer drugs enters clinical practice. FDA approved vepdegestrant (Veppanu·Arvinas) on May 1, 2026 for ESR1-mutated ER+/HER2- advanced·metastatic breast cancer — the first Proteolysis Targeting Chimera (PROTAC) class anticancer drug. VERITAC-2 trial PFS 5.0 months vs fulvestrant 2.1 months (43% risk reduction). 40~50% of patients post CDK4/6 + endocrine therapy progression have ESR1 mutations → broad target population. New mechanism of “degrading the protein away” enters hormone receptor-positive breast cancer treatment.
What Is PROTAC
Existing drug limitations:
- Most drugs use inhibition mechanism — bind active site of target protein to block activity
- Target protein itself remains alive
- More protein produced over time → ↓ effect
- Escape mutations like ESR1 mutation reduce effect
PROTAC:
- “Proteolysis Targeting Chimera”
- Directly degrades target protein
- Two-part molecule: one side binds target protein, other binds E3 ubiquitin ligase
- Tags target protein with ubiquitin → proteasome degrades target protein
- Target protein itself disappears
Vepdegestrant Mechanism
Structure:
- ER (estrogen receptor) binding site + E3 ligase binding site
- Connected by linker
Action:
- Binds ER (both ESR1 wild-type + mutant)
- Simultaneously binds E3 ligase (CRBN)
- Ubiquitin tagging on ER
- Proteasome degrades ER
- ↓ intracellular ER protein → blocks tumor growth
Difference from Existing SERDs
From L63 ESR1 mutation glossary, SERDs (Selective Estrogen Receptor Degrader):
1st-gen SERD (fulvestrant):
- ER binding·degradation
- But weak + injection required
- ↓ effect on ESR1 mutation
Next-gen oral SERDs (elacestrant·Orserdu, L63 etc):
- ER binding + degradation
- Oral
- Retains affinity for ESR1 mutations
- L63 EMERALD: PFS 8.6 months vs standard 1.9 months
PROTAC (Vepdegestrant·Veppanu):
- Stronger·deeper ER degradation
- E3 ligase utilization = ↑↑ degradation efficiency
- Effective on ESR1-mutated ER
- VERITAC-2: PFS 5.0 months vs fulvestrant 2.1 months (43% reduction)
VERITAC-2 Trial Results
Study design:
- 270 ESR1-mutated ER+/HER2- advanced·metastatic breast cancer patients
- Post CDK4/6 inhibitor + endocrine therapy progression
- Vepdegestrant monotherapy vs fulvestrant monotherapy
- Primary endpoint: progression-free survival (PFS)
Key results:
- PFS median:
- Vepdegestrant: 5.0 months
- Fulvestrant: 2.1 months
- HR 0.57 (43% reduction)
- Safety: mild~moderate side effects
- Serious adverse events: equivalent between groups
Clinical significance:
- New 2nd-line option for hormone receptor-positive breast cancer
- Stronger effect than fulvestrant
- Comparison data with elacestrant (L63) not available (different trials)
Meaning of ESR1 Mutation (L63 Recall)
ESR1 mutation:
- Develops in 30~40% post-1st-line in hormone receptor-positive breast cancer
- ER self-activates without estrogen
- Fulvestrant weak
Vepdegestrant target:
- Directly degrades ESR1-mutated ER
- Effective on both wild-type·mutant
- However, FDA indication is ESR1-mutated patients
Female Impact — Hormone Receptor-Positive Breast Cancer Ladder
Korean breast cancer statistics:
- 2024 new diagnoses ~30,000
- Average onset age 49
- 70% hormone receptor-positive (HR+)
Post-1st-line progression patient ladder (2026):
- 1st-line (CDK4/6 inhibitor + aromatase inhibitor)
- 2nd-line — ESR1 mutation liquid biopsy recommended
- If ESR1 mutated:
- Elacestrant (L63 EMERALD, PFS 8.6 months)
- Elacestrant + mTOR/CDK4/6 (L63 ELEVATE, PFS 13.8 months)
- Vepdegestrant (L67 VERITAC-2, PFS 5.0 months)
- 3rd-line+ — chemotherapy
Selection decision:
- Patient-specific suitability (physician decision)
- Side effect profile
- Insurance·access
Future of PROTAC — Beyond Cancer
Currently in PROTAC clinical trials:
- Tumors: AR (prostate cancer), BCL-XL, BTK etc
- Autoimmune: IRAK4
- Neurological: tau (Alzheimer’s), huntingtin (Huntington’s)
- HIV·viruses
PROTAC potential:
- Degradation more powerful than blocking
- Strong against escape mutations
- Big effect with small dose
- But molecular design difficult + safety needs additional validation
Hormone Receptor-Positive Breast Cancer 5-Layer Drug Matrix
L63~L67 integration:
| Stage | Drug | Source |
|---|---|---|
| 1st-line | CDK4/6 inhibitor + AI | Standard |
| 2nd (ESR1 mut) | Elacestrant mono | L63 EMERALD |
| 2nd (ESR1+mTOR) | Elacestrant + everolimus | L63 ELEVATE |
| 2nd (ESR1+CDK4/6) | Elacestrant + abemaciclib | L63 ELEVATE |
| 2nd (ESR1, PROTAC) | Vepdegestrant | L67 VERITAC-2 |
| 3rd+ | Chemo·anti-HER2 conjugate | Standard |
Side Effects·Cautions
VERITAC-2 reports:
- Mild fatigue·nausea·arthralgia
- Some hepatic enzyme elevation
- Serious adverse events equivalent to fulvestrant
Female-specific:
- No use during pregnancy·lactation
- Premenopausal patients: ovarian function suppression needed
- Bone density monitoring
Korean Clinical Significance
Veppanu Korean introduction outlook:
- Korean MFDS filing 1~2 years post US approval
- Insurance reimbursement negotiation additional 1~2 years
- Expected introduction: 2028~2029
- Specialty disease cost possible
Pricing estimate:
- US: $15,000~20,000/month
- Korean insurance: 5% patient burden
Conclusion
Vepdegestrant (Veppanu) FDA approval opens the clinical era of first PROTAC anticancer·protein degradation drugs. New option for ESR1-mutated hormone receptor-positive breast cancer patients. With L63 ESR1 molecular mechanism + elacestrant (EMERALD·ELEVATE) + L67 Vepdegestrant (VERITAC-2), the hormone receptor-positive breast cancer ladder deepens another step. The starting point of PROTAC expanding to tumors·autoimmune·neurological·viral. Above L66’s 5 pillars of precision·outpatient·daily penetration, another step of evolving precision medicine matrix.